APM
Avidity Partners Management Portfolio holdings
AUM
$499M
1-Year Est. Return
3.47%
1 Year Est. Return
+3.47%
AUM
$485M
AUM Growth
-$518M
(-52%)
Holding
82
Top Buys
| 1 | +$13.9M | |
| 2 | +$10.9M | |
| 3 | +$10.8M | |
| 4 |
Organon & Co
OGN
|
+$7.97M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$7.62M |
Top Sells
| 1 | +$33.8M | |
| 2 | +$28.2M | |
| 3 | +$26.1M | |
| 4 |
Dianthus Therapeutics
DNTH
|
+$20.9M |
| 5 |
Kymera Therapeutics
KYMR
|
+$20.1M |
Sector Composition
| 1 | Healthcare | 98.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Boston Scientific
BSX
$147B
| $33.9M | 6.46% |
336,000
-179,000
|
|
||
|
2
Dianthus Therapeutics
DNTH
$1.32B
| $31.2M | 5.95% |
1,720,902
-1,152,098
|
|
||
3
UnitedHealth
UNH
$300B
| $26.4M | 5.04% |
50,500
-9,500
|
|
||
4
CG Oncology
CGON
$2.98B
| $24M | 4.58% |
980,942
-116,858
|
|
||
5
Humana
HUM
$33.9B
| $21.4M | 4.08% |
81,000
-8,200
|
|
||
6
Natera
NTRA
$27B
| $16.9M | 3.21% |
119,200
-104,600
|
|
||
7
Regeneron Pharmaceuticals
REGN
$66B
| $16.1M | 3.07% |
25,400
+17,000
|
|
||
8
Exact Sciences
EXAS
$13.2B
| $15.3M | 2.91% |
353,000
-250,011
|
|
||
9
Beam Therapeutics
BEAM
$2.3B
| $13.9M | 2.64% |
+709,517
|
|
||
10
Glaukos
GKOS
$4.94B
| $13.2M | 2.51% |
134,000
-36,000
|
|
||
11
DexCom
DXCM
$23.9B
| $12.3M | 2.34% |
180,000
-138,000
|
|
||
12
Ultragenyx Pharmaceutical
RARE
$3.13B
| $11.7M | 2.22% |
322,100
-29,900
|
|
||
13
Syndax Pharmaceuticals
SNDX
$1.32B
| $11.4M | 2.17% |
925,000
-575,000
|
|
||
14
Cencora
COR
$66.8B
| $10.9M | 2.08% |
+39,300
|
|
||
15
Jazz Pharmaceuticals
JAZZ
$8.36B
| $9.93M | 1.89% |
80,000
-154,500
|
|
||
16
Tenet Healthcare
THC
$18.3B
| $9.68M | 1.85% |
72,000
-65,000
|
|
||
17
Neurocrine Biosciences
NBIX
$14.3B
| $9.48M | 1.81% |
85,700
-134,700
|
|
||
18
Danaher
DHR
$151B
| $9.12M | 1.74% |
44,500
-22,500
|
|
||
19
Axsome Therapeutics
AXSM
$6.79B
| $8.98M | 1.71% |
77,000
-111,000
|
|
||
20
Insmed
INSM
$39B
| $8.16M | 1.56% |
107,000
-125,800
|
|
||
|
21
Organon & Co
OGN
$1.69B
| $7.97M | 1.52% |
+535,000
|
|
||
22
Thermo Fisher Scientific
TMO
$212B
| $7.71M | 1.47% |
15,500
-29,100
|
|
||
23
Xenon Pharmaceuticals
XENE
$3.01B
| $7.68M | 1.46% |
229,000
-245,000
|
|
||
|
24
State Street SPDR S&P Biotech ETF
XBI
$6.26B
| $7.62M | 1.45% |
+94,000
|
|
||
|
CNTA
25
Centessa Pharmaceuticals
CNTA
$3.18B
| $7.61M | 1.45% |
529,000
-636,800
|
|